Nasdaq:VSTM
Verastem, Inc.
A preclinical-stage biopharmaceutical firm targeting rare diseases with a diverse therapeutic pipeline while managing significant cash burn to fund R&D activities.
Key Metrics
Investment Thesis
Bull Case
Investors may view Verastem as a high-risk, high-reward opportunity to gain exposure to potential blockbuster treatments in the rare disease space if their current pipeline candidates successfully advance through clinical trials and receive regulatory approval.", "The company's ability to generate $88.8M in cash reserves provides a runway to continue critical R&D efforts without immediate dilution, assuming strategic partnerships or grants are secured.
Bear Case
The company faces severe financial distress with negative shareholders' equity of $-28.9M and deepening annual losses from -$73.8M in 2022 to -$130.6M in 2024, indicating unsustainable burn rates without imminent commercialization or major capital infusion.", "With total liabilities exceeding assets ($130.4M vs $101.5M), the balance sheet is fragile and vulnerable to interest rate fluctuations given $4.6M in interest expenses against minimal operational cash generation.
About Verastem, Inc.
Verastem Inc. is a specialty pharmaceutical company focused on developing novel therapeutics for rare diseases and unmet medical needs, primarily serving markets in the United States and Europe through its pipeline of oncology and immunology candidates.
Analysis
Management Discussion
Despite generating $10.0M in revenue, the company reported a net loss of $-130.6M driven by substantial R&D expenditures of $81.3M and operating costs of $125.0M, resulting in negative cash flow from operations of $-104.8M which was partially offset by financing activities.
Industry Overview
The global rare disease therapeutics market is expanding rapidly due to an aging population and advances in gene therapy and small molecule technologies, offering significant growth potential for companies that can bring first-in-class treatments to patients with no current options.", "Competition is intense among biotech firms seeking funding and partnerships, requiring substantial capital investment to survive the long development cycles inherent in bringing new drugs to market.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $2.6M | — | $10.0M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $2.6M | — | $10.0M |
| Operating Expenses | $75.5M | — | $125.0M |
| Operating Income | $-72.9M | $-92.1M | $-115.0M |
| R&D | $50.6M | $61.4M | $81.3M |
| G&A | $25.0M | $30.7M | $43.6M |
| Stock-Based Comp | $6.0M | $5.9M | $7.3M |
| Depreciation | $118.0K | $62.0K | $26.0K |
| Other OpEx | $0 | — | $0 |
| Non-Operating Income | $-875.0K | $0 | $-15.5M |
| Interest Expense | $2.1M | $4.1M | $4.6M |
| Interest Income | $1.2M | $6.2M | $4.1M |
| Pre-Tax Income | $-73.8M | $-92.1M | $-130.5M |
| Income Tax | $0 | $-4.7M | $185.0K |
| Continuing Ops | $-73.8M | $-87.4M | $-130.6M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-73.8M | $-87.4M | $-130.6M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-73.8M | $-87.4M | $-130.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $92.9M | $143.7M | $95.0M |
| Cash & Equivalents | $74.9M | $77.9M | $88.8M |
| Prepaid Expenses | $4.9M | $6.6M | $5.9M |
| Other Current Assets | $13.0M | $59.2M | $200.0K |
| Long-Term Assets | $2.2M | $6.0M | $6.6M |
| PP&E (Net) | $92.0K | $37.0K | $32.0K |
| Operating Leases | $1.8M | $1.2M | $1.4M |
| Other LT Assets | $299.0K | $4.8M | $5.1M |
| Total Assets | $95.0M | $149.7M | $101.5M |
| Current Liabilities | $21.7M | $26.4M | $31.0M |
| Accounts Payable | $4.9M | $7.2M | $4.0M |
| Current Leases | $794.0K | $941.0K | $995.0K |
| Other Current Liab | $985.0K | $327.0K | $0 |
| Long-Term Liabilities | $26.0M | $44.8M | $99.5M |
| LT Operating Leases | $1.5M | $530.0K | $535.0K |
| Other LT Liab | $24.5M | $44.3M | $98.9M |
| Total Liabilities | $47.7M | $71.2M | $130.4M |
| Shareholders' Equity | $47.4M | $78.5M | $-28.9M |
| Retained Earnings | $-737.5M | $-824.9M | $-955.5M |
| AOCI | — | $13.0K | — |
| Total L&E | $95.0M | $149.7M | $101.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-73.8M | $-87.4M | $-130.6M |
| Non-Cash Adjustments | $8.7M | $-9.7M | $20.8M |
| Working Capital Changes | $1.4M | $10.6M | $5.1M |
| Cash from Operations | $-63.7M | $-86.5M | $-104.8M |
| Capital Expenditures | — | — | $28.0K |
| Cash from Investing | $66.2M | $-44.4M | $60.0M |
| Debt Repayments | — | $300.0K | — |
| Cash from Financing | $51.8M | $134.2M | $54.8M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $54.3M | $3.3M | $10.0M |
| Beginning Cash | $21.5M | $75.8M | $79.1M |
| Ending Cash | $75.8M | $79.1M | $89.1M |
Frequently Asked Questions
How does Verastem, Inc. make money?
The company operates primarily through its drug discovery and development segments, focusing on proprietary small molecule programs for oncology and other orphan indications without traditional commercial sales revenue streams in this reporting period.
What are the main risks for VSTM?
Complete reliance on successful progression of preclinical candidates given the high attrition rates in late-stage development, significant cash burn requiring dilutive capital raises, and potential loss of key intellectual property or failure to secure strategic partnerships.", "Limited current revenue generation exposing the company to liquidity constraints if external funding is delayed.
What is VSTM's competitive advantage?
Access to novel chemical entities with unique mechanisms of action for rare diseases, a strategic partnership ecosystem to mitigate R&D costs, and specialized expertise in navigating complex regulatory pathways for orphan drug designations.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.